Matches in Wikidata for { <http://www.wikidata.org/entity/Q90784010> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q90784010 description "artículu científicu espublizáu n'avientu de 2018" @default.
- Q90784010 description "im Dezember 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90784010 description "scientific article published on 01 December 2018" @default.
- Q90784010 description "wetenschappelijk artikel" @default.
- Q90784010 description "наукова стаття, опублікована в грудні 2018" @default.
- Q90784010 name "Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review" @default.
- Q90784010 name "Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review" @default.
- Q90784010 type Item @default.
- Q90784010 label "Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review" @default.
- Q90784010 label "Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review" @default.
- Q90784010 prefLabel "Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review" @default.
- Q90784010 prefLabel "Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review" @default.
- Q90784010 P1433 Q90784010-F63E9CBC-8B8C-4AD6-BCA3-710F69F61C14 @default.
- Q90784010 P1476 Q90784010-C5B17149-1F69-4274-A8D5-B780FCC78282 @default.
- Q90784010 P2093 Q90784010-281A4848-2B81-42DB-B0E6-FCA8738E59BF @default.
- Q90784010 P2093 Q90784010-47FFBE31-86BE-425F-A678-9E6B23E3E9ED @default.
- Q90784010 P2093 Q90784010-B5CEB7E4-C1F5-4E19-9673-1C9293FD6884 @default.
- Q90784010 P2093 Q90784010-ECA1C7CE-5B23-40B4-B101-6B0DF7D2BB6B @default.
- Q90784010 P2093 Q90784010-EF3C5907-340F-4460-BC6A-B71D96449706 @default.
- Q90784010 P304 Q90784010-540F19EA-D1AF-4DEE-8872-6138F53623BC @default.
- Q90784010 P31 Q90784010-0478C642-A6F4-4B5E-93B4-9F75D1ACEBE7 @default.
- Q90784010 P433 Q90784010-7C130F64-EE86-4061-B582-7F3997A4B2F7 @default.
- Q90784010 P478 Q90784010-093CC274-28D4-46D0-83D8-AE385C5DAF5B @default.
- Q90784010 P577 Q90784010-1EE57525-7B4E-49B8-9547-862A938777F7 @default.
- Q90784010 P698 Q90784010-657466E3-11E1-4952-B52B-A922AB4FD44E @default.
- Q90784010 P921 Q90784010-99226E0C-0AF1-4699-9C0F-8C20D0491419 @default.
- Q90784010 P698 30591425 @default.
- Q90784010 P1433 Q18620944 @default.
- Q90784010 P1476 "Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review" @default.
- Q90784010 P2093 "Heather W Goff" @default.
- Q90784010 P2093 "Hong Zhu" @default.
- Q90784010 P2093 "Jacob R Stewart" @default.
- Q90784010 P2093 "Neil Desai" @default.
- Q90784010 P2093 "Syed Rizvi" @default.
- Q90784010 P304 "764-774" @default.
- Q90784010 P31 Q13442814 @default.
- Q90784010 P433 "6" @default.
- Q90784010 P478 "28" @default.
- Q90784010 P577 "2018-12-01T00:00:00Z" @default.
- Q90784010 P698 "30591425" @default.
- Q90784010 P921 Q637059 @default.